Clinical Trials Logo

Constipation clinical trials

View clinical trials related to Constipation.

Filter by:

NCT ID: NCT03499808 Active, not recruiting - Constipation Clinical Trials

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Start date: June 6, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment. Monoclonal antibodies, such as isatuximab, may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT03395626 Active, not recruiting - Clinical trials for Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain

ID-JPL934 for Abnormal Bowel Movement

Start date: July 12, 2017
Phase: N/A
Study type: Interventional

Probiotics, which are part of the human body, are microorganisms, which are known to have beneficial effects when consumed in a certain amount, and have the function of controlling intestinal flora and inhibiting inflammation. Recently, probiotics have received much attention in the treatment of hypersensitivity syndrome. The aim of this study was to investigate the effect of probiotic strains, ID-JPL934, in the diagnosis of irritable bowel syndrome. Overall satisfaction with improvement of bowel habits such as diarrhea and constipation as well as abdominal discomfort and abdominal discomfort in the group receiving ID-JPL934 capsules (test food group or test group) and control group (control food group or control group) (0-10 point visual analogue scale) for each symptom before and after ingestion to evaluate the degree of improvement of the symptoms. The purpose of this study was to investigate the relationship between bacterial composition changes in the stool and the improvement of symptoms in the patients before and after ingestion.

NCT ID: NCT03119584 Active, not recruiting - Clinical trials for Chronic Constipation

Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

Start date: September 1, 2015
Phase: Phase 4
Study type: Interventional

Study includes 5 visits, when all basic clinical information, vital signs, symptoms, and side effects are going to be assessed at each appointment. Patients are going to be assigned by the computer, to receive an active or non-active drug for 14 days in a first phase. The order will be change during the second phase. The 2 weeks break without our medication will separate these phases. A very close observation regarding safety of our subjects will be implemented by study personnel and clinical investigators.

NCT ID: NCT02813356 Active, not recruiting - Clinical trials for Opioid Induced Constipation

Naloxegol US PMR CV Safety.

Start date: June 24, 2016
Phase:
Study type: Observational

The overall research goal for this study is to provide additional data to characterize the safety of naloxegol in patients aged 18 years and older who do not have a diagnosis of cancer and who are treated with opioids chronically

NCT ID: NCT02784093 Active, not recruiting - Fecal Impaction Clinical Trials

Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation

Start date: April 2015
Phase: Phase 2
Study type: Interventional

Fecal impaction (FI) is a common cause of lower gastrointestinal tract obstruction, and it is the result of chronic or severe constipation and most commonly found in the elderly population. Gastrografin is a water soluble contrast mediate that could act as an osmotic laxative. It has been shown to confer a therapeutic benefit in adhesive small bowel obstruction (SBO). The investigators speculate that gastrografin administrated orally may be more effective than enema in the treatment of fecal impaction induced intestinal obstruction.

NCT ID: NCT02571881 Active, not recruiting - Pain, Postoperative Clinical Trials

Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section

oksisektio
Start date: October 2012
Phase: Phase 4
Study type: Interventional

Constipation is common in pregnant women. Surgery, anaesthesia and opioid analgesics may further impair bowel function. The aim of the present study was to evaluate if oxycodone-naloxone combination compared to oxycodone reduced bowel dysfunction in patients undergoing caesarean section.

NCT ID: NCT02442115 Active, not recruiting - Constipation Clinical Trials

Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress

Start date: September 2009
Phase:
Study type: Observational

The clinical manifestation of autism spectrum disorder (ASD) is complex, with medical and mental health disruptions that occur with the three core behavioral criteria used for diagnosis (social behavior, communication, restricted interests/repetitive behavior). Co-occurring medical conditions, such as gastrointestinal dysfunction (GID), often are overlooked when designing research strategies to understand the mechanisms underlying the expression of ASD. This study was initially a collaboration between Children's Hospital Los Angeles (CHLA) and the Children's Hospital at Vanderbilt University. The current research project proposes to recruit subject at CHLA and the Center for Autism and Developmental Disorders (CAND), a Children's Hospital of Orange County and University of California Irvine (UCI) Health collaborative program. In Aim 1, the investigators will characterize GID in pediatric populations with ASD. Over a 12 month period, subjects will receive standard of care for their GID, typically functional constipation. The study population will be characterized with a standardized instrument for diagnosing functional GI disorders in children, the Questionnaire on Pediatric Gastrointestinal Symptoms, and with the clinical acumen of an experienced pediatric gastroenterologist. Nutritional information also will be collected to determine whether there are patterns of GIDs that correlate with dietary and nutritional status. The in-depth characterization and treatment of GIDs in children with ASD will provide a unique way of determining if ASD symptom and GID symptom improvement are related to each other. In Aim 2, the investigators will do in-depth assessment of each subjects functional status for social communication, emotional regulation, cognitive function, speech-language, sensory integration, and a biomarker of oxidative stress. The latter will be measured in urine samples over the course of one year. There are no direct interventions for autism symptoms in this study. Rather, subjects will receive standard of care for the GID diagnosis and secondary effects on ASD symptoms will be evaluated. Our power calculation shows that the investigators will be adequately powered with the proposed study design and recruitment targets. As part of the study, the investigators have developed a collaboration with investigators in the University of Southern California (USC) School of Engineering, in which the investigators will work with them to develop computational tools to assist in the characterization of videotaped Autism Diagnostic Observation Schedule (ADOS-2) assessments.

NCT ID: NCT02361749 Active, not recruiting - Clinical trials for Functional Constipation

Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation

Start date: September 2014
Phase: Phase 4
Study type: Interventional

Chronic idiopathic constipation is most common cause of Constipation in childhood with numerous cases in Egypt. Numerous conservative measures were tried but many fail. Surgical options include Longitudinal Myectomy of the muscle or injection of Botulinum toxin. Objectives: Comparative study between Botulinum toxin injection and Myectomy in treatment of Idiopathic Constipation

NCT ID: NCT02301221 Active, not recruiting - Clinical trials for Slow Transit Constipation

Effect of Fecal Microbiota Transplantation in Slow Transit Constipation

FMTSTC
Start date: March 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of fecal microbiota transplantation in adults with slow transit constipation.

NCT ID: NCT01863303 Active, not recruiting - Pain Clinical Trials

Epidemiological Study of Colorectal Cancer in WuHan

Start date: June 2012
Phase: N/A
Study type: Observational

The incidence risk of colorectal cancer (CRC) is increasing at 4.2% year by year in China. Most effective way to reduce the death rate of CRC patients is to diagnose in quite an early stage. QiaoKou District is a chemical industry Zone of Wuhan with a long history, which has few data of CRC epidemiology. The investigators design the primary CRC screening for this district by healthy questionnaire, Fecal Occult Blood Test(FOBT) and colonoscopy. HanYang Areo has been chosen as Control for its non-industry environment.The crowd would be screen biennially. The high risk group would be intervened, such as resection of polyps or other specific treatment. A follow-up registration database has been built for analysis the relationship between incidence or death rate to high risk factors, such as age, life environment, lifestyles, base diseases and family history of cancer. This study will provide some epidemiology dates of CRC to the local Government, and assist the governor to built a more effective screening system of CRC.